

Robbert G Van Der Most

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3863534/publications.pdf>

Version: 2024-02-01

29
papers

2,110
citations

361413

20
h-index

477307

29
g-index

33
all docs

33
docs citations

33
times ranked

3061
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults. <i>Journal of Infectious Diseases</i> , 2022, 225, 1915-1922. | 4.0 | 22 |
| 2 | Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. <i>Npj Vaccines</i> , 2022, 7, . | 6.0 | 32 |
| 3 | Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. <i>Nature</i> , 2021, 594, 253-258. | 27.8 | 253 |
| 4 | Antibody avidity, persistence, and response to antigen recall: comparison of vaccine adjuvants. <i>Npj Vaccines</i> , 2021, 6, 78. | 6.0 | 34 |
| 5 | The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination. <i>Cell</i> , 2021, 184, 3915-3935.e21. | 28.9 | 133 |
| 6 | Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. <i>Science Translational Medicine</i> , 2021, 13, . | 12.4 | 56 |
| 7 | Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. <i>Cell</i> , 2021, 184, 5432-5447.e16. | 28.9 | 131 |
| 8 | “World in motion” emulsion adjuvants rising to meet the pandemic challenges. <i>Npj Vaccines</i> , 2021, 6, 158. | 6.0 | 37 |
| 9 | Transcriptional profiles of adjuvanted hepatitis B vaccines display variable interindividual homogeneity but a shared core signature. <i>Science Translational Medicine</i> , 2020, 12, . | 12.4 | 33 |
| 10 | Role and plasticity of Th1 and Th17 responses in immunity to <i>Staphylococcus aureus</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2980-2992. | 3.3 | 19 |
| 11 | Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. <i>Vaccine</i> , 2019, 37, 3006-3021. | 3.8 | 72 |
| 12 | Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans. <i>Vaccine</i> , 2019, 37, 2004-2015. | 3.8 | 42 |
| 13 | Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types. <i>Expert Review of Vaccines</i> , 2019, 18, 309-322. | 4.4 | 15 |
| 14 | Adjuvant-Associated Peripheral Blood mRNA Profiles and Kinetics Induced by the Adjuvanted Recombinant Protein Candidate Tuberculosis Vaccine M72/AS01 in <i>Bacillus Calmette-Guérin</i> -Vaccinated Adults. <i>Frontiers in Immunology</i> , 2018, 9, 564. | 4.8 | 33 |
| 15 | Systems analysis of protective immune responses to RTS,S malaria vaccination in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2425-2430. | 7.1 | 249 |
| 16 | Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials. <i>Vaccine Journal</i> , 2017, 24, . | 3.1 | 21 |
| 17 | Cellular and molecular synergy in AS01-adjuvanted vaccines results in an early IFN γ response promoting vaccine immunogenicity. <i>Npj Vaccines</i> , 2017, 2, 25. | 6.0 | 171 |
| 18 | Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 90-102. | 3.3 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Predicting RTS,S Vaccine-Mediated Protection from Transcriptomes in a Malaria-Challenge Clinical Trial. <i>Frontiers in Immunology</i> , 2017, 8, 557. | 4.8 | 69 |
| 20 | Different Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. <i>Frontiers in Immunology</i> , 2017, 8, 943. | 4.8 | 111 |
| 21 | Impact of adjuvants on CD4+ T cell and B cell responses to a protein antigen vaccine: Results from a phase II, randomized, multicenter trial. <i>Clinical Immunology</i> , 2016, 169, 16-27. | 3.2 | 90 |
| 22 | Evaluation of potential immunogenicity differences between <i>Pandemrix</i> and <i>Arepanrix</i> . <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2289-2298. | 3.3 | 10 |
| 23 | Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting. <i>Vaccine</i> , 2015, 33, 4025-4034. | 3.8 | 110 |
| 24 | Narcolepsy and A(H1N1)pdm09 vaccination. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 572-576. | 3.3 | 11 |
| 25 | Comment on "CD4 ⁺ T Cell Autoimmunity to Hypocretin/Orexin and Cross-Reactivity to a 2009 H1N1 Influenza A Epitope in Narcolepsy". <i>Science Translational Medicine</i> , 2014, 6, 242le3. | 12.4 | 1 |
| 26 | Responses to A(H1N1)pdm09 Influenza Vaccines in Participants Previously Vaccinated With Seasonal Influenza Vaccine: A Randomized, Observer-Blind, Controlled Study. <i>Journal of Infectious Diseases</i> , 2014, 210, 1419-1430. | 4.0 | 16 |
| 27 | Seeking Help: B Cells Adapting to Flu Variability. <i>Science Translational Medicine</i> , 2014, 6, 246ps8. | 12.4 | 18 |
| 28 | H5N1 Influenza Vaccine Formulated with AS03A Induces Strong Cross-Reactive and Polyfunctional CD4 T-Cell Responses. <i>Journal of Clinical Immunology</i> , 2011, 31, 443-454. | 3.8 | 137 |
| 29 | Priming with AS03A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: An open non-randomised extension of a double-blind randomised primary study. <i>Vaccine</i> , 2010, 28, 849-857. | 3.8 | 127 |